Baylor Sammons Cancer Center Joins As Clinical Trial Site For Actinium Pharmaceuticals, Inc. (ATNM.OB)’s Actimab-A Clinical Trial
7/30/2014 9:56:29 AM
NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. The center joins several other clinical trial sites currently participating in the Actimab-A Phase I/II trial to potentially address the rapid mortality and unmet medical need for older patients with newly diagnosed acute myeloid leukemia (AML).
Help employers find you! Check out all the jobs and post your resume.
comments powered by